Clinical recommendations by Aminkeng et al. (2016) suggest pharmacogenomic testing for RARG rs2229774, SLC28A3 rs7853758 and UGT1A6 rs17863783 variants in childhood cancer patients indicated for doxorubicin or daunorubicin treatment. The gene discussed is SLC28A3; the disease is cancer.